Quest Magazine

International ALS Conference

ALS researchers from around the world gathered in Berlin, Germany, Dec. 8-10, to report on and discuss the latest research advances in this disease.

Daily updates from the symposium are available online at the Web sites of the Motor Neurone Disease Association (MNDA Symposium reports) and ALS Therapy Development Institute (ALS TDI Symposium reports). 

ALS Research: Poison Dirt?

New findings suggest a possible link between dust-dwelling bacterial toxins and an elevated incidence of ALS (amyotrophic lateral sclerosis) in Gulf War veterans.

The study blames cyanobacteria, microorganisms that live in desert sands and which can be inhaled when they’re kicked up in dust, such as when a convoy of military vehicles rumbles by. Cyanobacteria are common throughout the world in salt water, fresh water and soil.

ALS Research: Poison Dirt?

New findings suggest a possible link between dust-dwelling bacterial toxins and an elevated incidence of ALS (amyotrophic lateral sclerosis) in Gulf War veterans.

The study blames cyanobacteria, microorganisms that live in desert sands and which can be inhaled when they’re kicked up in dust, such as when a convoy of military vehicles rumbles by. Cyanobacteria are common throughout the world in salt water, fresh water and soil.

International ALS Conference

ALS researchers from around the world gathered in Berlin, Germany, Dec. 8-10, to report on and discuss the latest research advances in this disease.

ALS Drug Trial Restarted

A clinical trial of an experimental drug for ALS -- halted almost two years ago due to safety concerns –- has been given the green light to continue with a revised protocol, says CytRx Corp. of Los Angeles, the drug’s manufacturer.

ALS Drug Trial Restarted

A clinical trial of an experimental drug for ALS -- halted almost two years ago due to safety concerns –- has been given the green light to continue with a revised protocol, says CytRx Corp. of Los Angeles, the drug’s manufacturer.

The U.S. Food and Drug Administration placed a hold on the phase 2b trial of arimoclomol in January 2008, saying it wanted to see more toxicity data from previously completed animal studies. CytRx announced on Dec. 2, 2009, that it had received FDA permission to continue human testing.

New DMD Care Recommendations

A comprehensive set of clinical care recommendations for the diagnosis and management of Duchenne muscular dystrophy (DMD) is now available to medical professionals and families.

The complete recommendations,  in printable PDF format, can be read here:

Smoking Raises Risk of ALS

A new analysis says that smoking, already suspected of being a risk factor for amyotrophic lateral sclerosis (ALS), definitely is one. (See the 2004 story, Smoking Is Likely ALS Risk Factor, in MDA/ALS Newsmagazine.)

Gene Modifies Severity of LGMD2C

New research has shown that a change in a gene not previously connected to type 2C limb-girdle muscular dystrophy (LGMD2C) modifies the severity of the disease in mice and is likely to do the same in people with this and perhaps with related types of muscular dystrophy.

Gene Modifies Severity of LGMD2C

New research has shown that a change in a gene not previously connected to type 2C limb-girdle muscular dystrophy (LGMD2C) modifies the severity of the disease in mice and is likely to do the same in people with this and perhaps with related types of muscular dystrophy.

Pages